Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upifitamab rilsodotin maintenance in recurrent platinum-sensitive ovarian cancer
NCT05329545Phase 3Terminated
- Sponsor
- Mersana Therapeutics
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 3 trial of upifitamab rilsodotin in serous ovarian carcinoma (SOC), sponsored by Mersana Therapeutics. Started Jun 2022; status: terminated.
02
Drugs
upifitamab rilsodotin
03
Conditions
serous ovarian carcinoma (SOC)
Beyond the preview
Go deeper on NCT05329545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329545.